# WEZLANA® (ustekinumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ustekinumab

> The FDA approved WEZLANA® (ustekinumab), sponsored by JOHNSON & JOHNSON (JNJ), on May 5, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | WEZLANA® (ustekinumab) |
| Codes | CNTO-1275, CNTO1275 |
| Sponsor | JOHNSON & JOHNSON (JNJ) https://sec-api.dev/companies/jnj/catalysts |
| Indications | [Plaque Psoriasis](https://sec-api.dev/indications/plaque-psoriasis), [Crohn Disease](https://sec-api.dev/indications/crohn-disease), Arthritis, Juvenile |
| Modality | antibody |
| FDA designations | none disclosed |

## Timeline

### September 23, 2016: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761044 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20160923, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product STELARA (USTEKINUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761044%22

### Jan 2023: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2026-06-15, last confirmed 2026-06-16.
- SEC prospectus (424B) (accession 0000930413-26-001864): "In January 2023, we announced that the FDA had accepted for review a BLA for AVT04." https://www.sec.gov/Archives/edgar/data/1898416/000093041326001864/c116682_424b5.htm
- SEC prospectus (424B) (accession 0000930413-26-001857): "In January 2023, we announced that the FDA had accepted for review a BLA for AVT04." https://www.sec.gov/Archives/edgar/data/1898416/000093041326001857/c116682_424b5.htm

### Apr 2024: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-01-27, last confirmed 2025-01-27.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-000421): "In April 2024, the FDA approved SELARSDITM (ustekinumab-aekn) as a biosimilar to Stelara® (ustekinumab)." https://www.sec.gov/Archives/edgar/data/1898416/000117184325000421/exh_991.htm

### April 16, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-01-29, last confirmed 2026-09-03.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-000493): "On April 16, 2024, Alvotech and Teva announced that the FDA has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients six years and older." https://www.sec.gov/Archives/edgar/data/818686/000117184325000493/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-381899): "On April 16, 2024, the FDA approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara" https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033dex991.htm

### Oct 2024: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-02-24, last confirmed 2025-02-24.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-001021): "In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination of interchangeability for SELARSDI" https://www.sec.gov/Archives/edgar/data/1898416/000117184325001021/exh_991.htm

### November 13, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2024-11-13, last confirmed 2024-11-13.
- Press release filed with the SEC (EX-99) (accession 0001171843-24-006347): "Alvotech and Teva Pharmaceuticals announced that the U.S. FDA has approved a new presentation of SELARSDI (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab), in a 130 mg/26 mL single-dose vial for intravenous infusion." https://www.sec.gov/Archives/edgar/data/1898416/000117184324006347/exh_991.htm

### March 18, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2025-08-13, last confirmed 2025-08-13.
- Press release filed with the SEC (EX-99) (accession 0001898416-25-000009): "On 18 March 2025, the Company announced the FDA acceptance of BLA for AVT03." https://www.sec.gov/Archives/edgar/data/1898416/000189841625000009/alvo-20250630.htm

### May 5, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-05-05, last confirmed 2025-05-05.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-002743): "The U.S. FDA has approved SELARSDI (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April 30, 2025" https://www.sec.gov/Archives/edgar/data/1898416/000117184325002743/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-002743): "Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI (ustekinumab-aekn) with Stelara® (ustekinumab)" https://www.sec.gov/Archives/edgar/data/1898416/000117184325002743/exh_991.htm

### November 17, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Plaque Psoriasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06934226 (A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-11-17 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT06934226

### January 12, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Arthritis, Juvenile.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05083182 (A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT05083182

### April 15, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761044 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20260415, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product STELARA (USTEKINUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761044%22

### August 28, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761044 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20260828, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product STELARA (USTEKINUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761044%22

### Sep to Dec 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05092269 (A Long-term Extension Study of Ustekinumab in Pediatric Participants): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-29 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT05092269

### September 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05092269 (A Long-term Extension Study of Ustekinumab in Pediatric Participants): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-29 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT05092269

## Same indication

- [Otezla (apremilast)](https://sec-api.dev/pdufa/apremilast) (AMGN)
- [Sotyktu (deucravacitinib)](https://sec-api.dev/pdufa/deucravacitinib) (BMY)
- [Envudeucitinib](https://sec-api.dev/pdufa/envudeucitinib) (ALMS)
- [Tremfya (guselkumab)](https://sec-api.dev/pdufa/guselkumab) (JNJ)
- [ICOTYDE (icotrokinra)](https://sec-api.dev/pdufa/icotrokinra) (JNJ)
- [LY4395089](https://sec-api.dev/pdufa/ly4395089) (LLY)
- [Open-label envudeucitinib](https://sec-api.dev/pdufa/open-label-envudeucitinib) (ALMS)
- [ORKA-001](https://sec-api.dev/pdufa/orka-001) (ORKA)
- [Orka-001 induction dose](https://sec-api.dev/pdufa/orka-001-induction-dose) (ORKA)
- [ORKA-002](https://sec-api.dev/pdufa/orka-002) (ORKA)
- [Piclidenoson](https://sec-api.dev/pdufa/piclidenoson) (CANF)
- [TAK-279](https://sec-api.dev/pdufa/tak-279) (TAK)
- [Tapinarof cream, 1%](https://sec-api.dev/pdufa/tapinarof-cream-1) (OGN)
- [Tev-48574 dose regimen a](https://sec-api.dev/pdufa/tev-48574-dose-regimen-a) (TEVA)
- [Zasocitinib](https://sec-api.dev/pdufa/zasocitinib) (TAK)
- [Zl-1102 1% w/w gel bid for 16 weeks](https://sec-api.dev/pdufa/zl-1102-1-w-w-gel-bid-for-16-weeks) (ZLAB)

Calendar months: [September 2027](https://sec-api.dev/fda-calendar/2027-09)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ustekinumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "WEZLANA® (ustekinumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ustekinumab

```bibtex
@misc{secapidev_pdufa_ustekinumab_20261116,
  title        = {WEZLANA® (ustekinumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ustekinumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ustekinumab_20261116","title":"WEZLANA® (ustekinumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ustekinumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
